Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by
arterial and venous thrombotic manifestations and/or pregnancy-related complications in …

Background Rivaroxaban is established for the treatment and secondary prevention of
venous thromboembolism, but whether it is useful in patients with antiphospholipid …

Objective Antiphospholipid antibodies (aPL), especially those targeting β2‐glycoprotein I
(β2GPI), are well known to activate endothelial cells, monocytes, and platelets, with …

In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative
brought a diverse panel of experts in glomerular diseases together to discuss the 2012 …

Potentiation of neutrophil extracellular trap (NET) release is one mechanism by which
antiphospholipid antibodies (aPL Abs) effect thrombotic events in patients with …

The purpose of this task force was to critically analyze nine non-criteria manifestations of
APS to support their inclusion as APS classification criteria. The Task Force Members …

Current classification criteria for definite Antiphospholipid Syndrome (APS) require the use
of three laboratory assays to detect antiphospholipid antibodies (aCL, anti-β2GPI and LA) in …

Neuropsychiatric (NP) involvement in Systemic Lupus Erythematosus (SLE), can be a
severe and troubling manifestation of the disease that heavily impacts patient's health …

Hydroxychloroquine is an immunomodulatory drug that has been used for 60 years to treat
malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory …